Entyvio is not a TNF inhibitor. It belongs to a different class of biologic medications called integrin receptor antagonists. While both drug types treat inflammatory bowel disease, they work through completely different mechanisms in the body, and understanding that distinction matters if you’re comparing treatment options for ulcerative colitis or Crohn’s disease.
How Entyvio Actually Works
TNF inhibitors (like infliximab, adalimumab, and golimumab) block a protein called tumor necrosis factor, which drives inflammation throughout the body. Entyvio takes a different approach entirely. Its active ingredient, vedolizumab, targets a protein on the surface of immune cells called alpha-4-beta-7 integrin. This protein acts like a docking mechanism that allows immune cells to latch onto blood vessel walls in the gut and migrate into intestinal tissue.
By blocking that docking protein, Entyvio prevents immune cells from flooding into the gut lining where they would otherwise cause the chronic inflammation behind ulcerative colitis and Crohn’s disease. Specifically, it stops alpha-4-beta-7 from binding to a molecule called MAdCAM-1 on gut blood vessels. Think of it as intercepting immune cells before they can reach the battlefield rather than neutralizing the inflammatory signals they produce once they arrive.
Why the Distinction Matters
The biggest practical difference is where these drugs act. TNF inhibitors suppress inflammation system-wide, which is why they’re also used for conditions like rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Entyvio is gut-selective: it primarily affects immune cell trafficking to the intestines rather than dampening the immune system broadly. This targeted approach is the reason Entyvio is only approved for inflammatory bowel disease and not for joint or skin conditions.
That gut selectivity has implications for infection risk. A meta-analysis of 20 head-to-head studies found that in ulcerative colitis patients, Entyvio was associated with a lower risk of serious infections compared to TNF inhibitors (about 32% lower odds). In Crohn’s disease, however, the infection risk was roughly the same between the two drug classes. Overall serious infection rates for both types of medication run at approximately 5 per 100 person-years.
What Entyvio Treats
The FDA has approved Entyvio for two conditions in adults: moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease. The American Gastroenterological Association includes vedolizumab among its recommended therapies for moderate-to-severe ulcerative colitis, alongside TNF inhibitors and several other advanced therapies. Current AGA guidelines favor starting advanced therapies early rather than following a traditional step-up approach where patients must fail one drug class before trying another.
How Entyvio Compares to TNF Inhibitors for UC
In a retrospective study of 297 patients with moderate-to-severe ulcerative colitis, those receiving Entyvio as first-line therapy achieved a clinical remission rate of 82.3% at one year, compared to 77.4% for those on infliximab (a TNF inhibitor). The difference was not statistically significant, meaning the two drugs performed comparably. This is notable because TNF inhibitors have historically been the default first choice, yet the data suggests Entyvio holds its own as an initial treatment, particularly when you factor in its potentially lower infection risk in UC patients.
For Crohn’s disease, the picture is less clear-cut. TNF inhibitors have a longer track record and larger evidence base in Crohn’s, and the infection-risk advantage that Entyvio shows in UC doesn’t appear in Crohn’s studies.
How It’s Given
Entyvio is available as both an intravenous infusion and a subcutaneous injection. The IV version is administered in a clinic or infusion center, typically at weeks 0, 2, and 6 to start, then every 8 weeks for maintenance. The subcutaneous injection, which you can give yourself at home after the initial IV loading doses, offers more flexibility for long-term treatment. Your gastroenterologist will determine which format fits your situation.
Quick Comparison: Entyvio vs. TNF Inhibitors
- Drug class: Entyvio is an integrin receptor antagonist. TNF inhibitors include infliximab, adalimumab, and golimumab.
- Target: Entyvio blocks immune cell migration to the gut. TNF inhibitors neutralize an inflammatory protein throughout the body.
- Scope: Entyvio is gut-selective. TNF inhibitors act systemically and treat multiple inflammatory conditions.
- Infection risk in UC: Entyvio is associated with roughly 32% lower odds of serious infections compared to TNF inhibitors.
- Remission rates in UC: Comparable at one year (approximately 82% vs. 77%).